| Articolul precedent |
| Articolul urmator |
 |
 194 6 |
| Ultima descărcare din IBN: 2024-06-18 09:28 |
| Căutarea după subiecte similare conform CZU |
| 616.379:616.12 (1) |
| Заболевания пищеварительной системы. Болезнь пищеварительного тракта (1789) |
| Патология сердечно-сосудистой системы. Сердечно-сосудистые заболевания (1025) |
 SM ISO690:2012CARAMAN, Natalia. Preparatele antihipertensive la pacienții cu diabet zaharat. In: Interuniversitaria, Ed. 19, 4 mai 2023, Bălți. Bălți, Republica Moldova: Universitatea de Stat „Alecu Russo" din Bălţi, 2023, Ediția 19, Vol.3, pp. 139-149. ISBN 978-9975-50-303-7.. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Interuniversitaria Ediția 19, Vol.3, 2023 |
||||||
|
Conferința "Interuniversitaria" 19, Bălți, Moldova, 4 mai 2023 | ||||||
|
||||||
| CZU: 616.379:616.12 | ||||||
| Pag. 139-149 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Hypertension and diabetes are components of metabolic syndrome. The coexistence of these two diseases is associated with increased risk of cardio-vascular events. The microvascular and macrovascular complications are signi-ficantly more common unfavourable cardiovascular events. The first line of anti-hypertensive drug classes includ angiotensin-converting enzyme inhibitors, an-giotensin receptor blockers, calcium channel blockers, thiazide-like diuretics, mi-neralocorticoid receptor antagonists, and beta-blockers. The second-line anti-hypertensive drugs include α-blockers, renin inhibitors, loop diuretics, substan-ces affecting the central nervous system (methyldopa, clonidine), and vasodila-tors. The exact choice of hypotensive drugs depends on various factors: comorbi-dities, estimated glomerular filtration rate, side effects and ethnicity. |
||||||
| Cuvinte-cheie hypertension, diabetes mellitus, antihypertensive drugs, antihy-pertensive effect, metabolic disturbances |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-186180</cfResPublId> <cfResPublDate>2023</cfResPublDate> <cfVol>Ediția 19, Vol.3</cfVol> <cfStartPage>139</cfStartPage> <cfISBN>978-9975-50-306-8.</cfISBN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/186180</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Preparatele antihipertensive la pacienții cu diabet zaharat</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>hypertension; diabetes mellitus; antihypertensive drugs; antihy-pertensive effect; metabolic disturbances</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Hypertension and diabetes are components of metabolic syndrome. The coexistence of these two diseases is associated with increased risk of cardio-vascular events. The microvascular and macrovascular complications are signi-ficantly more common unfavourable cardiovascular events. The first line of anti-hypertensive drug classes includ angiotensin-converting enzyme inhibitors, an-giotensin receptor blockers, calcium channel blockers, thiazide-like diuretics, mi-neralocorticoid receptor antagonists, and beta-blockers. The second-line anti-hypertensive drugs include α-blockers, renin inhibitors, loop diuretics, substan-ces affecting the central nervous system (methyldopa, clonidine), and vasodila-tors. The exact choice of hypotensive drugs depends on various factors: comorbi-dities, estimated glomerular filtration rate, side effects and ethnicity.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-16378</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-16378</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-16378-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Caraman</cfFamilyNames> <cfFirstNames>Natalia</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>
|
|
|
